Allogeneic bone marrow transplantation for lymphoma

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Registry data show that use of allogeneic transplantation for non-Hodgkin's lymphoma, and to a lesser extent, Hodgkin's disease is increasing. Although no prospective randomized trials have been performed, most comparisons show a significantly lower relapse rate when allogeneic transplant results are compared to results of autologous hematopoietic stem cell transplantation. The lower relapse rate following allogeneic transplantation, as well as several other lines of evidence, support the existence of a graft-versus-lymphoma effect. Nevertheless, in most comparisons, the lower relapse rate following allogeneic transplantation is offset by higher transplant-related mortality. These results make it difficult to find situations where definite overall survival advantages associated with the use of allogeneic transplantation can be demonstrated. The use of low-intensity non-myeloablative regimens for allogeneic transplantation is attracting attention. It is hoped that this approach may harness a graft-versus-lymphoma effect with less morbidity and mortality than conventional allogeneic transplantation, but more data are required to assess the value of this treatment. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalBlood Reviews
Volume14
Issue number1
DOIs
StatePublished - Mar 2000

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Lymphoma
Transplants
Recurrence
Mortality
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Registries
Morbidity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Allogeneic bone marrow transplantation for lymphoma. / Bierman, Philip Jay.

In: Blood Reviews, Vol. 14, No. 1, 03.2000, p. 1-13.

Research output: Contribution to journalReview article

@article{bbf3df781e7e496ebf32428e0baa63e8,
title = "Allogeneic bone marrow transplantation for lymphoma",
abstract = "Registry data show that use of allogeneic transplantation for non-Hodgkin's lymphoma, and to a lesser extent, Hodgkin's disease is increasing. Although no prospective randomized trials have been performed, most comparisons show a significantly lower relapse rate when allogeneic transplant results are compared to results of autologous hematopoietic stem cell transplantation. The lower relapse rate following allogeneic transplantation, as well as several other lines of evidence, support the existence of a graft-versus-lymphoma effect. Nevertheless, in most comparisons, the lower relapse rate following allogeneic transplantation is offset by higher transplant-related mortality. These results make it difficult to find situations where definite overall survival advantages associated with the use of allogeneic transplantation can be demonstrated. The use of low-intensity non-myeloablative regimens for allogeneic transplantation is attracting attention. It is hoped that this approach may harness a graft-versus-lymphoma effect with less morbidity and mortality than conventional allogeneic transplantation, but more data are required to assess the value of this treatment. (C) 2000 Harcourt Publishers Ltd.",
author = "Bierman, {Philip Jay}",
year = "2000",
month = "3",
doi = "10.1054/blre.1999.0125",
language = "English (US)",
volume = "14",
pages = "1--13",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation for lymphoma

AU - Bierman, Philip Jay

PY - 2000/3

Y1 - 2000/3

N2 - Registry data show that use of allogeneic transplantation for non-Hodgkin's lymphoma, and to a lesser extent, Hodgkin's disease is increasing. Although no prospective randomized trials have been performed, most comparisons show a significantly lower relapse rate when allogeneic transplant results are compared to results of autologous hematopoietic stem cell transplantation. The lower relapse rate following allogeneic transplantation, as well as several other lines of evidence, support the existence of a graft-versus-lymphoma effect. Nevertheless, in most comparisons, the lower relapse rate following allogeneic transplantation is offset by higher transplant-related mortality. These results make it difficult to find situations where definite overall survival advantages associated with the use of allogeneic transplantation can be demonstrated. The use of low-intensity non-myeloablative regimens for allogeneic transplantation is attracting attention. It is hoped that this approach may harness a graft-versus-lymphoma effect with less morbidity and mortality than conventional allogeneic transplantation, but more data are required to assess the value of this treatment. (C) 2000 Harcourt Publishers Ltd.

AB - Registry data show that use of allogeneic transplantation for non-Hodgkin's lymphoma, and to a lesser extent, Hodgkin's disease is increasing. Although no prospective randomized trials have been performed, most comparisons show a significantly lower relapse rate when allogeneic transplant results are compared to results of autologous hematopoietic stem cell transplantation. The lower relapse rate following allogeneic transplantation, as well as several other lines of evidence, support the existence of a graft-versus-lymphoma effect. Nevertheless, in most comparisons, the lower relapse rate following allogeneic transplantation is offset by higher transplant-related mortality. These results make it difficult to find situations where definite overall survival advantages associated with the use of allogeneic transplantation can be demonstrated. The use of low-intensity non-myeloablative regimens for allogeneic transplantation is attracting attention. It is hoped that this approach may harness a graft-versus-lymphoma effect with less morbidity and mortality than conventional allogeneic transplantation, but more data are required to assess the value of this treatment. (C) 2000 Harcourt Publishers Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0034050711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034050711&partnerID=8YFLogxK

U2 - 10.1054/blre.1999.0125

DO - 10.1054/blre.1999.0125

M3 - Review article

C2 - 10805257

AN - SCOPUS:0034050711

VL - 14

SP - 1

EP - 13

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -